Samia Mora, MD, MHS
Dr. Samia Mora is an Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts. She is a cardiovascular medicine specialist at the Brigham and Women’s Hospital, where she is the Director of the Center for Lipid Metabolomics. Dr. Mora’s research focuses on risk factors and prevention of cardiovascular disease.
Dr. Mora received her undergraduate degree from Harvard University, and her medical degree from Harvard Medical School. She completed an internal medicine residency at Massachusetts General Hospital and a cardiovascular disease fellowship at The Johns Hopkins Hospital, where she also obtained a Masters in Health Science (Epidemiology) from the Johns Hopkins Bloomberg School of Public Health.
She is board certified in cardiovascular disease and echocardiography, and is a Fellow of the American Heart Association, American College of Cardiology, and American Society of Echocardiography. She also serves on the Editorial Boards of JAMA Internal Medicine and Atherosclerosis. Dr. Mora is an Elected Member of the Association for University Cardiologists and the American Society for Clinical Investigation.
In This Episode We Discuss
- Understanding lipoprotein types: HDL, LDL, IDL, VLDL, Chlyomicrons, chylomicron remnants, Lp(a)
- Lipoproteins vs. cholesterol content: LDL vs. LDL-C
- Role of lipoproteins in atherosclerosis
- What increases the probability of a particle penetrating the arterial wall
- Clinically relevant markers for risk: TC? LDL-C? NHDL-C? TC/HDL-C?
- Are small, dense LDL more atherogenic than large LDL particles?
- Concordance & discordance: LDL-C and: LDL-P, ApoB
- What % of the population have ApoB # discordant with LDL-C?
- The most informative markers to test for an individual looking at monitoring their CVD/atherosclerosis risk
Links & Resources
- Sigma Statement: Cholesterol, Lipoproteins & Lipids: Understanding CVD Risk
- Cholesterol Insights and Controversies From the UK Biobank Study – Mora et al., 2019 Editorial piece in Circulation (PDF)
- The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering (PDF)
- Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM (PDF)
- Quantifying Atherogenic Lipoproteins: A Consensus Statement from EAS and EFLM
- Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL